Radionuclide therapy is an established practice within University College London Hospital.
Currently we receive referrals both
nationally and internationally for the treatment of a range of
conditions including neuroendocrine tumours (NETs), thyroid carcinoma,
meningioma and pituitary tumours.
We also provide conventional
radioiodine therapy on an out-patient basis for the treatment of
We are one of only two centres in the UK to offer paediactric radionuclide therapy.
Within UCLH, we have 10 dedicated rooms for Radionuclide
These are state-of-the-art, en-suite and lead-lined with a separate room situated adjacent that is designated for comforters and carers.
We offer state-of-the-art diagnostic imaging assessment to monitor eligibility for radionuclide therapy, incorporating 123I-mIBG (Metaiodobenzylguanidine) scintigraphy, 18F-FDG and 68Ga-DOTATATE PETCT. Additionally, assessments can be performed on the PET/MR machine located in the UCLH cancer centre. This is the first machine of its kind in the UK.
Referrals for therapy are discussed in multi-disciplinary meetings comprising a range of medical, scientific and technical staff, where case histories are reviewed together with imaging studies.
A recent addition to the service is the use of 177Lu-DOTATATE therapy to treat patients with Neuroblastomas. 68Ga-DOTATATE PET/CT is used to scan children with neuroblastoma and identify those suitable for radionuclide therapy with 177Lu-DOTATATE. We have shown, for what is to our knowledge the first time, that treatment with 177Lu-DOTATATE is safe and feasible in children with relapsed or primary refractory high-risk neuroblastomas.